Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that its Board of Directors has appointed Michael M. Goldberg, M.D. as President and Chief Executive Officer effective September 22, 2016. The Board of Directors has also appointed Eric K. Rowinsky M.D., a Navidea board member since 2010, as Chairman of Navidea’s Board, a position previously held by Dr. Goldberg, who will remain a board member.
“We are delighted to announce the appointment of Michael as Navidea’s
CEO,” said Dr. Rowinsky, Chairman of Navidea’s Compensation, Nominating
and Governance committee and newly appointed Chairman. “Dr. Goldberg is
a visionary leader with a deep knowledge and appreciation for the
potential of Navidea’s macrophage targeting technology platform and its
wide range of diagnostic and therapeutic applications. At this important
transition point for the Company, we will benefit greatly from his
expertise as we drive the development of our Manocept™ clinical
immunodiagnostic and immunotherapeutic programs to deliver targeted
products to improve patient outcomes.”
“I look forward to spearheading the growth of both Navidea and
Macrophage Therapeutics as we execute our mission to not only diagnose
but treat disease,” said Michael M. Goldberg, M.D. “The combination of
exceptional technology, a strong leadership team as well as our
expectation of improved financial stability will allow us to effectively
execute on our strategy to more rapidly advance on numerous development
programs with our ground-breaking proprietary technology for multiple
high value indications.”
Michael M. Goldberg, M.D. has been a member of the Navidea Board of
Directors since November 2013, serving as interim Chief Executive
Officer from May to October 2014. Dr. Goldberg is currently a Managing
Partner of Montaur Capital Partners. Prior to this role, he served as
the Chairman of the Board and Chief Executive Officer of Emisphere
Technologies, Inc., the pioneer in the development of oral delivery
technologies for macromolecules. Prior to Emisphere, he served as Vice
President in Investment Banking of The First Boston Corporation, where
he was a founding member of the Healthcare Banking Group. Dr. Goldberg
graduated from the accelerated six year combined BS/MD program from
Rensselaer Polytechnic Institute and the Albany Medical College in 1982,
and obtained an M.B.A. from the Graduate School of Business, Columbia
University, in 1985.
Eric K. Rowinsky, M.D. has extensive research and drug development
experience, oncology expertise, corporate strategy and broad scientific
and medical knowledge and has served as a director of Navidea since July
2010. He is currently Executive Chairman and President, of Rgenix, Inc.
During his career, Dr. Rowinsky has held executive positions at Stemline
Therapeutics, Inc., Primrose Therapeutics, and ImClone Systems
Incorporated. Prior to that, Dr. Rowinsky held several positions at the
Cancer Therapy & Research Center’s Institute of Drug Development,
including Director of the Institute, Director of Clinical Research and
SBC Endowed Chair for Early Drug Development, and concurrently served as
Clinical Professor of Medicine in the Division of Medical Oncology at
the University of Texas Health Science Center at San Antonio. Dr.
Rowinsky was an Associate Professor of Oncology at the Johns Hopkins
University School of Medicine. Dr. Rowinsky is a member of the boards of
directors of Biogen Inc. and Fortress Biosciences, Inc., publicly-held
life sciences companies. He is also an Adjunct Professor of Medicine at
New York University.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products and platforms including Manocept™
and NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical decision-making,
targeted treatment and, ultimately, patient care. Lymphoseek®
(technetium Tc 99m tilmanocept) injection, Navidea’s first commercial
product from the Manocept platform, was approved by the FDA in March
2013 and in Europe in November 2014. The development activities of the
Manocept immunotherapeutic platform will be conducted by Navidea in
conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel products and advancing the Company’s pipeline
through global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which relate to
other than strictly historical facts, such as statements about the
Company’s plans and strategies, expectations for future financial
performance, new and existing products and technologies, anticipated
clinical and regulatory pathways, and markets for the Company’s products
are forward-looking statements within the meaning of the Act. The words
“believe,” “expect,” “anticipate,” “estimate,” “project,” and similar
expressions identify forward-looking statements that speak only as of
the date hereof. Investors are cautioned that such statements involve
risks and uncertainties that could cause actual results to differ
materially from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, our ability to
repay our debt, the outcome of the CRG litigation, reliance on third
party manufacturers, accumulated deficit, future capital needs,
uncertainty of capital funding, dependence on limited product line and
distribution channels, competition, limited marketing and manufacturing
experience, risks of development of new products, regulatory risks and
other risks detailed in the Company’s most recent Annual Report on Form
10-K and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements.